CoChat
Sign Up
Cited by 27Hypothalamic control of reproductive hormonesReproductive Biology and FertilityOvarian function and disorders

Ablation of folliculogenesis in women by a single dose of gonadotropin-releasing hormone agonist: significance of time in cycle

Open access
Monroe, Scott E., Henzl, Milan R., Martin, Mary C., Schriock, Eldon, Lewis, Vivian, Nerenberg, Clint, Jaffe, Robert B.·1985·Fertility and Sterility
DOI 10.1016/s0015-0282(16)48432-3
Open this paper in CoChat — free account

Abstract

Effects of single subcutaneous doses (1, 5, 20, and 100 micrograms) of nafarelin, a potent gonadotropin-releasing hormone agonist, on the physiologic events of the human menstrual cycle were studied in 28 normal women. Nafarelin entered the circulation rapidly after injection. Peak concentrations were observed within 1 hour, and the plasma half-life was 4 to 5 hours. Maximal concentrations of luteinizing hormone and follicle-stimulating hormone were reached 3 to 4 hours after nafarelin administration. The magnitude of the gonadotropin responses depended both on the phase of the menstrual cycle (smallest responses during the early follicular phase) and the dose of nafarelin. Nafarelin administration during the early follicular phase delayed ovulation by 4.6 +/- 1.7 (standard deviation) days and prolonged the duration of the menstrual cycle from a pretreatment length of 29.2 +/- 2.1 days to 33.4 +/- 4.0 days (P less than 0.001). When nafarelin was administered shortly before or after ovulation, cycle length was not altered consistently. Administration 5 to 10 days after ovulation resulted in a truncated luteal phase. These observations suggest that the hormonal events triggered by nafarelin during the early follicular phase temporarily arrest the process of selection of the dominant follicle. Repeated intermittent administration of nafarelin or other gonadotropin-releasing hormone agonists in the early follicular phase may prevent follicular maturation and ovulation and may be a practical approach to contraceptive development.

Integrity signals

Registry

Crossref · 10.1016/s0015-0282(16)48432-3

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A modified menstrual cycle model based on the Margolskee 2011 model was used with optimal control theory to determine the minimum total exogenous estrogen/progesterone dose and timing of administration to induce anovulation.

    “Utilized optimal control theory on a modified menstrual cycle model (based on Margolskee 2011 model) to determine the minimum total exogenous estrogen/progesterone dose and timing of administration to induce anovulation (absence of ovulation)”

    From A Survey of Mathematical Modeling of Hormonal Contraception and the Menstrual Cycle (2024) · cites this paper as [61]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Monroe, S. E., Henzl, M. R., Martin, M. C., Schriock, E., Lewis, V., Nerenberg, C., & Jaffe, R. B.
Affiliations
University of California, San Francisco (US)
ORCID
Martin, Mary C.
Venue
Fertility and Sterility
Publisher
Elsevier BV
Published
1985-03
Volume
43
Issue
3
Pages
361-368
ISSN
0015-0282 (ISSN-L)
DOI
10.1016/s0015-0282(16)48432-3
OpenAlex
W2275981118
Cited by
27
References
18
Citations by year
2024: 1 · 2022: 1 · 2014: 1 · 2012: 1
FWCI
3.15
Type
journal article
Language
en
Open access
Licence
Locations
  • Fertility and Sterility (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eunice Kennedy Shriver National Institute of Child Health and Human Development (N01-HD-0-2811)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Biology and Fertility
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Keywords
nafarelin, GnRH agonist, folliculogenesis, menstrual cycle, follicular phase, ovulation, luteinizing hormone, follicle-stimulating hormone, dominant follicle selection, luteal phase, contraceptive development, dose-response relationship
MeSH terms
Adult, Contraceptive Agents, Female, Estradiol, Female, Follicular Phase, Follicle Stimulating Hormone, Ovarian Follicle, Humans, Injections, Subcutaneous, Kinetics, Luteinizing Hormone, Gonadotropin-Releasing Hormone, Luteal Phase, Middle Aged, Ovulation, Progesterone, Time Factors, Nafarelin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review